CIK 0001870404 · <br>Emerging growth company
CERO THERAPEUTICS HOLDINGS, INC.
Sign in to watch- Tickers
- CERO CEROW
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 871088814
- Phone
- 650-407-2376
- Business address
- 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- CERO THERAPEUTICS HOLDINGS, INC., PHOENIX BIOTECH ACQUISITION CORP.
Securities
- CERO Common stock OTC
- CEROW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-14 | Fisher Douglas Carl President | Other acquisition | +43,300 | 43,300 | ||
| 2024-02-14 | Fisher Douglas Carl President | Grant or award · Series A Convertible Preferred Stock | +50 | $1,000.00 | $50K | 50 |
| 2024-02-14 | Fisher Douglas Carl President | Other acquisition · Warrants | +5,000 | 5,000 | ||
| 2024-02-14 | PHOENIX BIOTECH SPONSOR, LLC 10% owner | Other disposition | −1,125,000 | 4,171,246 | ||
| 2024-02-14 | PHOENIX BIOTECH SPONSOR, LLC 10% owner | Other disposition | −4,171,246 | 1,000,000 | ||
| 2024-02-14 | PHOENIX BIOTECH SPONSOR, LLC 10% owner | Option exercise · Convertible Promissory Note | −0 | 0 | ||
| 2024-02-14 | PHOENIX BIOTECH SPONSOR, LLC 10% owner | Option exercise · Series A Convertible Preferred Stock | +1,555 | $1,000.00 | $1.6M | 1,555 |
| 2024-02-14 | PHOENIX BIOTECH SPONSOR, LLC 10% owner | Other disposition · Series A Convertible Preferred Stock | −1,555 | $1,000.00 | $1.6M | 0 |
| 2024-02-14 | PHOENIX BIOTECH SPONSOR, LLC 10% owner | Other disposition · Warrants | −349,998 | 0 | ||
| 2024-02-14 | LAPORTE KATHLEEN Director | Other acquisition | +5,828 | 5,828 | ||
| 2024-02-14 | LAPORTE KATHLEEN Director | Grant or award · Series A Convertible Preferred Stock | +50 | $1,000.00 | $50K | 50 |
| 2024-02-14 | Ehrlich Christopher B Director | Other disposition | −1,125,000 | 4,171,246 | ||
| 2024-02-14 | Ehrlich Christopher B Director | Other disposition | −4,171,246 | 1,000,000 | ||
| 2024-02-14 | Ehrlich Christopher B Director | Other acquisition | +478,825 | 478,825 | ||
| 2024-02-14 | Ehrlich Christopher B Director | Other acquisition | +3,600 | 3,600 | ||
| 2024-02-14 | Ehrlich Christopher B Director | Option exercise · Convertible Promissory Note | −0 | 0 | ||
| 2024-02-14 | Ehrlich Christopher B Director | Option exercise · Series A Convertible Preferred Stock | +1,555 | $1,000.00 | $1.6M | 1,555 |
| 2024-02-14 | Ehrlich Christopher B Director | Other disposition · Series A Convertible Preferred Stock | −1,555 | $1,000.00 | $1.6M | 0 |
| 2024-02-14 | Ehrlich Christopher B Director | Grant or award · Series A Convertible Preferred Stock | +100 | $1,000.00 | $100K | 100 |
| 2024-02-14 | Ehrlich Christopher B Director | Other acquisition · Series A Convertible Preferred Stock | +175 | $1,000.00 | $175K | 275 |
Page 5 of 6 · 120 trades